Dr Jari Rautio, Plexpress’ CEO, will be at stand 32 along with the rest of the Plexpress team to discuss the benefits of ADME-Tox screening using the TRAC approach, as well as to outline some successful recent projects completed by the company. These include the analysis of human cytochrome P450 expression in primary hepatocytes and the screening of ADME-Tox markers from rat liver samples. They will also be providing details of Plexpress’ integrated gene expression service, which offers a ‘one-stop-
As part of its offering, Plexpress also provides pre-validated TRAC ADME-Tox panels designed to yield excellent performance when working with human and rat models during pre-clinical drug testing. The company can also develop custom panels of up to 30 genes for any species with known sequence data, based on customer requests. For more information please visit the Plexpress website at www.plexpress.com.